# PF-07284892 in Participants With Advanced Solid Tumors

> **NCT04800822** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 53 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** PF-07284892
- **DRUG:** lorlatinib
- **DRUG:** binimetinib
- **BIOLOGICAL:** cetuximab
- **DRUG:** encorafenib

## Key facts

- **NCT ID:** NCT04800822
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-17
- **Primary completion:** 2024-06-19
- **Final completion:** 2024-06-19
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04800822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04800822, "PF-07284892 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04800822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*